Athersys and Chugai Enter License Agreement and Collaboration to Develop MultiStem(R) Cell Therapy for Ischemic Stroke in Japan
Regenerative Medicine Partnership Focused on Development of Novel Stem Cell Therapy
CLEVELAND and TOKYO, March 2, 2015 (GLOBE NEWSWIRE) — Athersys, Inc. (Nasdaq:ATHX) and Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4519) have announced a partnership and license agreement to exclusively develop and commercialize MultiStem® cell therapy for ischemic stroke in Japan. Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan’s aging population.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.